UFP Technologies, Inc. (UFPT)
| Market Cap | 2.49B +57.4% |
| Revenue (ttm) | 631.64M +7.3% |
| Net Income | 72.30M +7.7% |
| EPS | 9.25 +7.3% |
| Shares Out | 7.75M |
| PE Ratio | 34.80 |
| Forward PE | 32.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,356 |
| Open | 320.78 |
| Previous Close | 325.00 |
| Day's Range | 317.71 - 326.72 |
| 52-Week Range | 173.86 - 338.71 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 355.00 (+10.28%) |
| Earnings Date | Aug 3, 2026 |
About UFPT
UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment ... [Read more]
Financial Performance
In 2025, UFP Technologies's revenue was $602.80 million, an increase of 19.50% compared to the previous year's $504.42 million. Earnings were $68.31 million, an increase of 15.82%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for UFPT stock is "Buy." The 12-month stock price target is $355.0, which is an increase of 10.28% from the latest price.
News
UFP Technologies Earnings Call Transcript: Q2 2026
Q2 2026 saw 15.1% sales growth, record adjusted EPS, and broad-based MedTech strength. Gross margin improved, backlog and labor issues were resolved, and investments in capacity and leadership support future growth. Organic growth is expected to normalize in the target range.
UFP Technologies Earnings release: Q2 2026
UFP Technologies released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
UFP Technologies Quarterly report: Q2 2026
UFP Technologies has published its Q2 2026 quarterly earnings report on August 4, 2026.
UFP Technologies reports Q2 adjusted EPS $2.92, consensus $2.56
Reports Q2 revenue $174.0M, consensus $159.38M. The company said, “Our second quarter and first-half results reflect solid execution across the platform and continued progress toward our long-term gro...
UFP Technologies Announces Record Q2 Results
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, s...
UFP Technologies to Report Second Quarter 2026 Financial Results on August 3, 2026
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, s...
UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Mitchell Rock, President and Chief Executive Officer, and Ron Lataille, Sr. Vice President, Treasurer a...
UFP Technologies Transcript: 16th Annual East Coast IDEAS Conference
A new CEO leads a seasoned team, maintaining a strategy focused on organic growth and targeted M&A in the medtech CDMO sector. The company targets 12–18% annual revenue growth, prioritizes high-value segments like robotic surgery and patient beds, and leverages global operations and supplier partnerships for durable, diversified growth.
UFP Technologies Slides: Investor presentation
UFP Technologies has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th in New York, NY
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Mitchell Rock, Chief Executive Officer, and Ron Lataille, Sr. Vice President, Treasurer and Chief Finan...
UFP Technologies Names Ryan Stafford General Counsel and Senior Vice President of Human Resources
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization specializing in single-use and single-patient medical devices, today a...
UFP Technologies Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by majority vote. Final voting results will be published in a Form 8-K filing.
UFP Technologies Earnings Call Transcript: Q1 2026
Revenue grew 4.1% year-over-year, led by strong medical segment growth and new program launches, while non-medical sales declined as automotive is phased out. Margin improvement is expected in the second half as new programs ramp and cost headwinds subside.
UFP Technologies Earnings release: Q1 2026
UFP Technologies released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
UFP Technologies Quarterly report: Q1 2026
UFP Technologies has published its Q1 2026 quarterly earnings report on May 5, 2026.
UFP Technologies reports Q1 adjusted EPS $2.48, consensus $2.31
Reports Q1 revenue $154.2M, consensus $154.78M. “I am pleased with our first quarter results and continued progress with our strategic initiatives,” said Jeffrey Bailly, Chairman and CEO. “Revenue gre...
UFP Technologies Announces Strong Q1 Results
NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, tod...
UFP Technologies to Report First Quarter 2026 Financial Results on May 4, 2026
NEWBURYPORT, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient me...
UFP Technologies Proxy statement: Proxy filing
UFP Technologies filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
UFP Technologies Transcript: 47th Annual Raymond James Institutional Investor Conference
A leading CDMO in medical devices leverages exclusive material access, strategic acquisitions, and deep customer partnerships to drive high-margin growth. Recent contract extensions, robust financial performance, and expansion into new geographies position the company for continued outperformance.
UFP Technologies Slides: Investor presentation
UFP Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
UFP Technologies targeting 12%-18% revenue growth in 3-5 years
Other 3-5 year financial targets include 28%-31% gross margin and 17%-20% operating margin. Comments taken from investor presentation slides.
UFP Technologies to Present and Host 1X1 Investor Meetings at the Raymond James 47th Annual Institutional Investors Conference
NEWBURYPORT, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient med...
UFP Technologies Earnings Call Transcript: Q4 2025
Revenue grew 19.5% to $602.8M, with strong gains in operating income and EPS. Labor inefficiencies and a cybersecurity breach were managed effectively, and robust growth is expected in patient services and medical submarkets, supported by contract extensions and facility expansions.
UFP Technologies Annual report: Q4 2025
UFP Technologies has published its Q4 2025 annual report on February 25, 2026.